{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:27:45Z","timestamp":1792207665867,"version":"4.4.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell\u2013based therapies have shown remarkable efficacy in multiple myeloma (MM), yet the disease remains largely incurable. MM cells secrete excessive monoclonal immunoglobulins (M proteins) that drive complications but are inaccessible to chimeric antigen receptor (CAR) T-cell or antibody targeting. Here, we investigated the constant domains of the immunoglobulin heavy chain (IGH) as novel targets for therapeutic T-cell receptors (TCRs) after confirming high and homogeneous IGH expression in &amp;gt;95% of patients with MM. Peptides from immunoglobulin A and immunoglobulin G constant regions were eluted from HLA-A\u221702:01, and reactive TCRs were isolated from healthy donors using allo-HLA-A\u221702:01 presentation to circumvent self-tolerance. T cells engineered with TCRs specific for IgA or IgG passed a stringent multitier safety screen and selectively eliminated HLA-A\u221702:01+ MM cells from 20 patients secreting the relevant IgH in vitro. In vivo, IgA-TCR T cells eradicated IgA+HLA-A\u221702:01+ MM cells in xenograft models and reduced circulating IgA in humanized mice. These findings establish immunoglobulin constant domains as viable TCR targets in MM, potentially making \u223c40% of patients of European descent eligible for TCR T-cell therapy, and extension to additional HLA alleles could further broaden eligibility. The approach may also be applicable to lymphoma and antibody-mediated autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031897","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:38:04Z","timestamp":1772476684000},"page":"1984-1997","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["TCR T cells targeting IgA- and IgG-expressing multiple myeloma"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-2232","authenticated-orcid":false,"given":"Karolos","family":"Douvlataniotis","sequence":"first","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-3924","authenticated-orcid":false,"given":"Aleksei","family":"Titov","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0189-0561","authenticated-orcid":false,"given":"Julia","family":"Zeun","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6149-5444","authenticated-orcid":false,"given":"Merve","family":"Bilici","sequence":"additional","affiliation":[{"name":"3Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyilimu","family":"Palashati","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-2693","authenticated-orcid":false,"given":"Waywen","family":"Loh","sequence":"additional","affiliation":[{"name":"4Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-4963","authenticated-orcid":false,"given":"Even Holth","family":"Rustad","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-5003","authenticated-orcid":false,"given":"Trung The","family":"Tran","sequence":"additional","affiliation":[{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"},{"name":"5Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2445-1258","authenticated-orcid":false,"given":"Fridtjof","family":"Lund-Johansen","sequence":"additional","affiliation":[{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"},{"name":"5Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Chand","family":"Bollineni","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-2045","authenticated-orcid":false,"given":"Jessica D.","family":"Kepple","sequence":"additional","affiliation":[{"name":"4Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9818-1054","authenticated-orcid":false,"given":"Luis P.","family":"Huth","sequence":"additional","affiliation":[{"name":"6Berlin Center for Advanced Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"7Berlin Institute of Health Center for Regenerative Therapies, Berlin Institute of Health, Berlin, Germany"},{"name":"8Institute of Medical Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-3654","authenticated-orcid":false,"given":"Ludvig A.","family":"Munthe","sequence":"additional","affiliation":[{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"},{"name":"5Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-3506","authenticated-orcid":false,"given":"Thorstein","family":"Boxaspen","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"},{"name":"9Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"9Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-1220","authenticated-orcid":false,"given":"Anders","family":"Waage","sequence":"additional","affiliation":[{"name":"10Research Department, St Olavs Hospital and Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-3579","authenticated-orcid":false,"given":"Dimitrios L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"6Berlin Center for Advanced Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"7Berlin Institute of Health Center for Regenerative Therapies, Berlin Institute of Health, Berlin, Germany"},{"name":"8Institute of Medical Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"11Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX"},{"name":"12Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX"},{"name":"13Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-0917","authenticated-orcid":false,"given":"Katherine R.","family":"Bull","sequence":"additional","affiliation":[{"name":"4Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-3849","authenticated-orcid":false,"given":"Joanna","family":"Hester","sequence":"additional","affiliation":[{"name":"3Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-7732","authenticated-orcid":false,"given":"Fadi","family":"Issa","sequence":"additional","affiliation":[{"name":"3Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5342-8145","authenticated-orcid":false,"given":"Eirini","family":"Giannakopoulou","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3100","authenticated-orcid":false,"given":"Johanna","family":"Olweus","sequence":"additional","affiliation":[{"name":"1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"},{"name":"2The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026101511215297100_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2026101511215297100_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"2026101511215297100_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama-Journal Am Med Assoc"},{"issue":"9","key":"2026101511215297100_bib4","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2026101511215297100_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"2026101511215297100_bib6","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026101511215297100_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026101511215297100_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"6220","key":"2026101511215297100_bib9","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"2","key":"2026101511215297100_bib10","first-page":"83","article-title":"Epidemiology of the M-component immunoglobulin types of multiple myeloma","volume":"4","author":"Herrinton","year":"1993","journal-title":"Cancer Causes Control"},{"issue":"4","key":"2026101511215297100_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00277-022-04783-1","article-title":"Revisiting the impact of immunoglobulin isotypes in multiple myeloma","volume":"101","author":"Bal","year":"2022","journal-title":"Ann Hematol"},{"issue":"7","key":"2026101511215297100_bib12","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"17","key":"2026101511215297100_bib13","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","article-title":"Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"key":"2026101511215297100_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2022.10.005","article-title":"Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms","volume":"130","author":"Qiu","year":"2022","journal-title":"Hum Pathol"},{"issue":"1","key":"2026101511215297100_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01076.x","article-title":"Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma","volume":"81","author":"Belle","year":"2008","journal-title":"Eur J Haematol"},{"issue":"4","key":"2026101511215297100_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0167-5699(99)01443-7","article-title":"Immunotherapy with CTLs restricted by nonself MHC","volume":"20","author":"Stauss","year":"1999","journal-title":"Immunol Today"},{"issue":"6","key":"2026101511215297100_bib17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","article-title":"Induction of neoantigen-reactive T cells from healthy donors","volume":"14","author":"Ali","year":"2019","journal-title":"Nat Protoc"},{"issue":"4","key":"2026101511215297100_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41587-021-01089-x","article-title":"T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes","volume":"40","author":"Ali","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2026101511215297100_bib19","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"2026101511215297100_bib20","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41590-025-02252-1","article-title":"TCR-engineered T cells targeting a shared beta-catenin mutation eradicate solid tumors","volume":"26","author":"Eggebo","year":"2025","journal-title":"Nat Immunol"},{"key":"2026101511215297100_bib21","unstructured":"Multiple Myeloma Research Foundation CoMMpass study. Accessed 5 March 2026. https:\/\/research.themmrf.org\/."},{"issue":"12","key":"2026101511215297100_bib22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ajh.25641","article-title":"Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma","volume":"94","author":"Rustad","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"2026101511215297100_bib23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","article-title":"TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1","volume":"129","author":"Jahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026101511215297100_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-023-01408-6","article-title":"Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain","volume":"16","author":"Meeuwsen","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2026101511215297100_bib25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/bloodadvances.2022008460","article-title":"Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed\/refractory multiple myeloma","volume":"7","author":"Nishihori","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026101511215297100_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair","year":"2009","journal-title":"Br J Haematol"},{"issue":"W1","key":"2026101511215297100_bib69","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"2026101511215297100_bib27","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","article-title":"Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability","volume":"66","author":"Cohen","year":"2006","journal-title":"Cancer Res"},{"issue":"10","key":"2026101511215297100_bib28","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"2026101511215297100_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41541-023-00713-y","article-title":"A systematic safety pipeline for selection of T-cell receptors to enter clinical use","volume":"8","author":"Foldvari","year":"2023","journal-title":"NPJ Vaccin"},{"key":"2026101511215297100_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol"},{"issue":"24","key":"2026101511215297100_bib31","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026101511215297100_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","article-title":"Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival","volume":"6","author":"Chen","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2026101511215297100_bib33","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/bcj.2013.37","article-title":"A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo","volume":"3","author":"Glauer","year":"2013","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026101511215297100_bib34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","article-title":"Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92","volume":"132","author":"Morelli","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101511215297100_bib35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2023-180828","article-title":"ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed\/refractory multiple myeloma [abstract]","volume":"142","author":"Oliver-Caldes","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026101511215297100_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1097\/TP.0000000000003177","article-title":"Humanization of immunodeficient animals for the modeling of transplantation, graft versus host disease, and regenerative medicine","volume":"104","author":"Adigbli","year":"2020","journal-title":"Transplantation"},{"issue":"12","key":"2026101511215297100_bib37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41568-025-00857-0","article-title":"Targeting the roots of myeloid malignancies with T cell receptors","volume":"25","author":"Foldvari","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2026101511215297100_bib38","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: association of RAS\/RAFmutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"2026101511215297100_bib39","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2026101511215297100_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-019-0636-8","article-title":"Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma","volume":"11","author":"Loffler","year":"2019","journal-title":"Genome Med"},{"issue":"10","key":"2026101511215297100_bib41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026101511215297100_bib42","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"19","key":"2026101511215297100_bib43","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2026101511215297100_bib44","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"2026101511215297100_bib45","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1182\/blood.V128.22.4428.4428","article-title":"Free light chain escape in multiple myeloma: an exceptional phenomenon [abstract]","volume":"128","author":"Caillon","year":"2016","journal-title":"Blood"},{"key":"2026101511215297100_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.exphem.2017.09.010","article-title":"Characterization and use of the novel human multiple myeloma cell line MC-B11\/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain","volume":"57","author":"Walters","year":"2018","journal-title":"Exp Hematol"},{"issue":"1","key":"2026101511215297100_bib47","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"2026101511215297100_bib48","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1016\/j.clml.2019.09.120","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"19","author":"Sarin","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026101511215297100_bib49","doi-asserted-by":"crossref","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"Oncoimmunology"},{"issue":"20","key":"2026101511215297100_bib50","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/bloodadvances.2023010410","article-title":"Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma","volume":"7","author":"Wachsmann","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026101511215297100_bib51","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.ymthe.2025.02.035","article-title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells","volume":"33","author":"Wachsmann","year":"2025","journal-title":"Mol Ther"},{"issue":"3","key":"2026101511215297100_bib52","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/jha2.731","article-title":"Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies","volume":"4","author":"Shohdy","year":"2023","journal-title":"Ejhaem"},{"issue":"4","key":"2026101511215297100_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"2026101511215297100_bib54","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2026101511215297100_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A\u221702(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2026101511215297100_bib56","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.4049\/jimmunol.167.10.5565","article-title":"Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory","volume":"167","author":"Suresh","year":"2001","journal-title":"J Immunol"},{"issue":"6","key":"2026101511215297100_bib57","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/TP.0b013e31819b5a58","article-title":"Assessment of belatacept-mediated costimulation blockade through evaluation of CD80\/86-receptor saturation","volume":"87","author":"Latek","year":"2009","journal-title":"Transplantation"},{"issue":"25","key":"2026101511215297100_bib58","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2017-02-769463","article-title":"c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals","volume":"130","author":"Nishimura","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026101511215297100_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","article-title":"A costimulatory CAR improves TCR-based cancer immunotherapy","volume":"10","author":"Omer","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"2026101511215297100_bib60","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1128\/JVI.00027-09","article-title":"Therapeutic memory T cells require costimulation for effective clearance of a persistent viral infection","volume":"83","author":"Garidou","year":"2009","journal-title":"J Virol"},{"issue":"9","key":"2026101511215297100_bib61","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"issue":"7","key":"2026101511215297100_bib62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloma after allogeneic stem cell transplantation","volume":"24","author":"Groger","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026101511215297100_bib63","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"2026101511215297100_bib64","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2026101511215297100_bib65","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026101511215297100_bib66","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2024-193205","article-title":"Hypogammaglobulinemia and daratumumab in multiple myeloma: risk factors, infections, immunoglobulin replacement, and mortality [abstract]","volume":"144","author":"Hong","year":"2024","journal-title":"Blood"},{"issue":"7647","key":"2026101511215297100_bib67","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"22","key":"2026101511215297100_bib68","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1182\/blood.V128.22.914.914","article-title":"Endogenous immunoglobulin-derived neoepitopes are processed and form a sizeable fraction of the HLA class I ligandome of human lymphoma cells [abstract]","volume":"128","author":"van Bergen","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/1984\/2594910\/blood_bld-2025-031897-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/1984\/2594910\/blood_bld-2025-031897-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:22:07Z","timestamp":1792077727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/16\/1984\/566892\/TCR-T-cells-targeting-IgA-and-IgG-expressing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":69,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031897","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,10,15]]}}}